Vor Biopharma Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $321.5M | $93.3M | $94.3M | $64.6M | $47.5M | $31.6M |
| SG&A Expense | — | $50.1M | $27.9M | $31.7M | $28.9M | $21.5M | $11.7M |
| Operating Income | — | $-371.6M | $-121.2M | $-126.0M | $-93.4M | $-69.0M | $-43.4M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | — | $-696.0M | $-116.9M | $-117.9M | $-92.1M | $-68.9M | $-43.3M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-70.50 | $-11.34 | $-0.58 | $-0.78 | $-0.70 | $-76.86 |
| EPS (Diluted) | — | $-70.50 | $-11.34 | $-0.58 | $-0.78 | $-0.70 | $-76.86 |
| Shares Outstanding (Basic) | 48.8M | 9.9M | 10.3M | 201.6M | 118.7M | 100.3M | 1.5M |
| Shares Outstanding (Diluted) | 48.8M | 9.9M | 10.3M | 201.6M | 118.7M | 100.3M | 1.5M |
| Dividends Per Share | — | — | — | — | — | — | — |